valganciclovir and Lymphoma--Primary-Effusion

valganciclovir has been researched along with Lymphoma--Primary-Effusion* in 2 studies

Other Studies

2 other study(ies) available for valganciclovir and Lymphoma--Primary-Effusion

ArticleYear
Case report of a primary effusion lymphoma successfully treated with oral valganciclovir after failing chemotherapy.
    Hematological oncology, 2018, Volume: 36, Issue:1

    Primary effusion lymphoma is a rare non-Hodgkin lymphoma that presents with pleural effusions and lacking of tumour mass. It is universally associated with human herpesvirus 8 (HHV8) and is more frequent among immunosuppressed patients. There is no standard treatment, chemotherapy and anti-HIV therapy have been used with poor results, but there is still no strong evidence supporting the use of valganciclovir. We present the case of a HIV positive man that presented with pleural effusion compatible with primary effusion lymphoma and positivity for HHV8 DNA in blood. Bortezomib-containing treatment protocol was started, but the disease progressed within the chemotherapy. Therefore, treatment with oral valganciclovir was decided and the patient achieved a sustained radiological complete response. HHV8 DNA turned negative 6 months after starting the treatment with valganciclovir.

    Topics: Administration, Oral; Ganciclovir; Humans; Lymphoma, Primary Effusion; Male; Middle Aged; Valganciclovir

2018
Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient.
    European journal of haematology, 2013, Volume: 91, Issue:5

    Primary effusion lymphoma (PEL) is a human herpesvirus 8 (HHV8) associated lymphoproliferative disease characterized by effusions in body cavities, and lack of tumor mass. Valganciclovir is a treatment option in PEL, however, little is known about its clinical efficacy. Ganciclovir has been reported to be effective in HHV8(+) multicentric Castleman's disease (MCD) by decreasing the plasma HHV8 load, which is an important factor in the induction and persistence of MCD, Kaposi's sarcoma (KS), and PEL. But there is no information about the efficacy of valganciclovir on HHV8 associated lymphoproliferative diseases. Here, we present the first EBV and HIV negative, HHV8 positive PEL case treated with valganciclovir; for whom it initially reduced the viral load leading to a transient partial improvement in the clinical status, but failed to induce a complete and durable remission.

    Topics: Aged; Antiviral Agents; Fatal Outcome; Ganciclovir; Herpesviridae Infections; Herpesvirus 8, Human; Humans; Lymphoma, Primary Effusion; Male; Treatment Failure; Valganciclovir; Viral Load

2013